Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:IONS 22 August 2025 - 25 August 2025

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····

Stock Market Today

  • Lumentum's Potential 'Nvidia Moment' Highlights Market Attention
    April 9, 2026, 11:09 AM EDT. Lumentum Technologies is drawing comparisons to Nvidia due to its promising growth in the tech sector. Economist James Foord, leading The Pragmatic Investor group, highlights Lumentum's potential to replicate Nvidia's market success. The Pragmatic Investor offers diverse insights including global macro trends, international equities, commodities, and tech stocks. Foord emphasizes building robust, diversified portfolios that preserve and increase wealth amid evolving market conditions. Investors are advised to consider the company's position carefully, though no stock recommendations are made. The discussion underscores the importance of strategic investment amid dynamic technology developments.

Latest article

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

9 April 2026
Grab Holdings launched 13 new AI-powered products in Jakarta, including a “Group Ride” feature that can cut fares by up to 40% for shared routes. CEO Anthony Tan said the tools aim to offset rising fuel costs and support demand as households tighten spending. The company’s 2026 revenue and profit forecasts remain below analyst expectations. Grab’s $600 million deal to buy Foodpanda Taiwan is pending regulatory approval.
Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

9 April 2026
Nokia was named a Leader and Outperformer in GigaOm’s 2026 Radar for data center switching for the fifth year in a row, competing with Cisco, Arista, and HPE Juniper. Shares fell 1.05% in Helsinki ahead of Thursday’s annual meeting, where board changes and a dividend of up to 14 euro cents per share will be considered.
American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

9 April 2026
The FAA proposed a $255,000 civil penalty against American Airlines, alleging the carrier allowed 12 flight attendants who tested positive for drugs or alcohol to return to safety-sensitive duties before completing required follow-up tests. The alleged violations occurred from May 2019 to December 2023. American has 30 days to respond. The airline said it is reviewing the notice.
Go toTop